STOCK TITAN

[SCHEDULE 13G] PALISADE BIO, INC. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary

Palisade Bio, Inc. received a Schedule 13G filing disclosing that Point72-related entities and Steven A. Cohen beneficially own 7,585,611 shares of common stock, representing 6.2% of the outstanding class as of 10/06/2025. The filing states the shares are held by Point72 Associates, an investment fund managed by Point72 Asset Management, with Point72 Capital Advisors, Inc. as general partner and Mr. Cohen exercising control. The reporting persons certify the position was not acquired to influence control of the issuer and they filed jointly under a Joint Filing Agreement.

Palisade Bio, Inc. ha ricevuto una presentazione Schedule 13G che rende noto che entità correlate a Point72 e Steven A. Cohen detengono beneficiariamente 7.585.611 azioni ordinarie, pari al 6,2% delle azioni in circolazione al 10/06/2025. La presentazione afferma che le azioni sono detenute da Point72 Associates, un fondo di investimento gestito da Point72 Asset Management, con Point72 Capital Advisors, Inc. come socio accomandante e il signor Cohen che esercita il controllo. Le persone che riportano certificano che la posizione non è stata acquistata per influenzare il controllo dell'emittente e hanno presentato congiuntamente ai sensi di un Joint Filing Agreement.
Palisade Bio, Inc. recibió una presentación Schedule 13G que revela que las entidades relacionadas con Point72 y Steven A. Cohen poseen beneficiosamente 7.585.611 acciones ordinarias, que representan el 6,2% de la clase en circulación a partir del 10/06/2025. La presentación indica que las acciones están en manos de Point72 Associates, un fondo de inversión gestionado por Point72 Asset Management, con Point72 Capital Advisors, Inc. como socio general y el Sr. Cohen ejerciendo control. Las personas que reportan certifican que la posición no fue adquirida para influir en el control del emisor y presentaron conjuntamente bajo un Joint Filing Agreement.
Palisade Bio, Inc.은 Schedule 13G 제출을 받아 Point72 관련 기관과 Steven A. Cohen이 우선적으로 7,585,611주(일반주)를 소유하고 있으며, 이는 10/06/2025 현재 발행주식의 6.2%에 해당함을 공개했습니다. 제출서에 의하면 이 주식은 Point72 Associates( Point72 Asset Management가 관리하는 투자펀드) 가 보유하고 있으며, Point72 Capital Advisors, Inc.가 일반 파트너로, Cohen 씨가 지배권을 행사하고 있습니다. 보고 당사자들은 이 포지션이 발행자의 지배권에 영향을 미치기 위해 취득된 것이 아님을 확인하고 Joint Filing Agreement에 따라 공동으로 제출했다고 명시합니다.
Palisade Bio, Inc. a reçu un dépôt Schedule 13G révélant que des entités liées à Point72 et Steven A. Cohen détiennent bénéficiairement 7 585 611 actions ordinaires, représentant 6,2% de la classe en circulation au 10/06/2025. Le dépôt indique que les actions sont détenues par Point72 Associates, un fonds d'investissement géré par Point72 Asset Management, avec Point72 Capital Advisors, Inc. comme partenaire général et M. Cohen exerçant le contrôle. Les personnes déclarantes certifient que la position n'a pas été acquise pour influencer le contrôle de l'émetteur et elles ont déposé conjointement en vertu d'un Joint Filing Agreement.
Palisade Bio, Inc. hat eine Schedule 13G-Einreichung erhalten, die bekanntgibt, dass Point72-bezogene Einheiten und Steven A. Cohen die Aktien der Stammaktien in beneficial ownership halten: 7.585.611 Aktien, was 6,2% der ausstehenden Klasse entspricht zum 10/06/2025. Die Einreichung gibt an, dass die Aktien von Point72 Associates gehalten werden, ein Investmentfonds, der von Point72 Asset Management verwaltet wird, wobei Point72 Capital Advisors, Inc. als General Partner fungiert und Herr Cohen die Kontrolle ausübt. Die meldenden Personen bestätigen, dass die Position nicht erworben wurde, um die Kontrolle des Emittenten zu beeinflussen, und sie haben gemeinsam unter einer Joint Filing Agreement eingereicht.
تلقت Palisade Bio, Inc. رد Schedule 13G يكشف أن الكيانات المرتبطة بـ Point72 وشخص ستيفن آ. كوهن يملكون بشكل مفيد 7,585,611 سهماً من الأسهم العادية، مما يمثل 6.2% من الفئة القائمة حتى 10/06/2025. ينص الإيداع أن الأسهم مملوكة من قبل Point72 Associates، صندوق استثمار تديره Point72 Asset Management، مع Point72 Capital Advisors, Inc. كشريك عام والسيد Cohen يمارس السيطرة. يؤكد مقدمو التقارير أن الموقف لم يُكتسب بهدف التأثير على سيطرة المُصدر وقد قدّموا بشكل مشترك بموجب Joint Filing Agreement.
Positive
  • Clear disclosure of a 6.2% stake (7,585,611 shares) improves market transparency
  • Joint Filing Agreement unifies reporting across Point72 entities and the named individual, reducing investor uncertainty
Negative
  • Shared voting and dispositive power indicates coordinated control pathways despite certification of passive intent
  • 6.2% position is material enough to merit monitoring for future escalation to active ownership filings

Insights

TL;DR: Point72 reports a passive 6.2% stake, improving disclosure and investor visibility.

The filing identifies 7,585,611 shares held for Point72 Associates with shared voting and dispositive power reported, and lists the reporting chain linking Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen.

This is a routine, non‑control disclosure; investors should note the 6.2% level as a meaningful, but non‑controlling, block and watch for any future amendments or a Schedule 13D which would indicate an active intent to influence governance over coming weeks to months.

TL;DR: Shared voting/dispositive power implies coordinated influence potential despite a stated passive intent.

The report shows shared voting and dispositive power over the same 7,585,611 shares for each reporting person, reflecting the managerial and control relationships among the entities named.

Key dependencies include the filing's certification of non‑control intent; monitor any change in voting power or additional filings that would alter governance implications within the next quarter.

Palisade Bio, Inc. ha ricevuto una presentazione Schedule 13G che rende noto che entità correlate a Point72 e Steven A. Cohen detengono beneficiariamente 7.585.611 azioni ordinarie, pari al 6,2% delle azioni in circolazione al 10/06/2025. La presentazione afferma che le azioni sono detenute da Point72 Associates, un fondo di investimento gestito da Point72 Asset Management, con Point72 Capital Advisors, Inc. come socio accomandante e il signor Cohen che esercita il controllo. Le persone che riportano certificano che la posizione non è stata acquistata per influenzare il controllo dell'emittente e hanno presentato congiuntamente ai sensi di un Joint Filing Agreement.
Palisade Bio, Inc. recibió una presentación Schedule 13G que revela que las entidades relacionadas con Point72 y Steven A. Cohen poseen beneficiosamente 7.585.611 acciones ordinarias, que representan el 6,2% de la clase en circulación a partir del 10/06/2025. La presentación indica que las acciones están en manos de Point72 Associates, un fondo de inversión gestionado por Point72 Asset Management, con Point72 Capital Advisors, Inc. como socio general y el Sr. Cohen ejerciendo control. Las personas que reportan certifican que la posición no fue adquirida para influir en el control del emisor y presentaron conjuntamente bajo un Joint Filing Agreement.
Palisade Bio, Inc.은 Schedule 13G 제출을 받아 Point72 관련 기관과 Steven A. Cohen이 우선적으로 7,585,611주(일반주)를 소유하고 있으며, 이는 10/06/2025 현재 발행주식의 6.2%에 해당함을 공개했습니다. 제출서에 의하면 이 주식은 Point72 Associates( Point72 Asset Management가 관리하는 투자펀드) 가 보유하고 있으며, Point72 Capital Advisors, Inc.가 일반 파트너로, Cohen 씨가 지배권을 행사하고 있습니다. 보고 당사자들은 이 포지션이 발행자의 지배권에 영향을 미치기 위해 취득된 것이 아님을 확인하고 Joint Filing Agreement에 따라 공동으로 제출했다고 명시합니다.
Palisade Bio, Inc. a reçu un dépôt Schedule 13G révélant que des entités liées à Point72 et Steven A. Cohen détiennent bénéficiairement 7 585 611 actions ordinaires, représentant 6,2% de la classe en circulation au 10/06/2025. Le dépôt indique que les actions sont détenues par Point72 Associates, un fonds d'investissement géré par Point72 Asset Management, avec Point72 Capital Advisors, Inc. comme partenaire général et M. Cohen exerçant le contrôle. Les personnes déclarantes certifient que la position n'a pas été acquise pour influencer le contrôle de l'émetteur et elles ont déposé conjointement en vertu d'un Joint Filing Agreement.
Palisade Bio, Inc. hat eine Schedule 13G-Einreichung erhalten, die bekanntgibt, dass Point72-bezogene Einheiten und Steven A. Cohen die Aktien der Stammaktien in beneficial ownership halten: 7.585.611 Aktien, was 6,2% der ausstehenden Klasse entspricht zum 10/06/2025. Die Einreichung gibt an, dass die Aktien von Point72 Associates gehalten werden, ein Investmentfonds, der von Point72 Asset Management verwaltet wird, wobei Point72 Capital Advisors, Inc. als General Partner fungiert und Herr Cohen die Kontrolle ausübt. Die meldenden Personen bestätigen, dass die Position nicht erworben wurde, um die Kontrolle des Emittenten zu beeinflussen, und sie haben gemeinsam unter einer Joint Filing Agreement eingereicht.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Point72 Asset Management, L.P.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:10/07/2025
Point72 Capital Advisors, Inc.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:10/07/2025
Steven A. Cohen
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:10/07/2025
Exhibit Information

Exhibit 99.1: Joint Filing Agreement

FAQ

What stake did Point72 report in Palisade Bio (PALI)?

Point72 reported beneficial ownership of 7,585,611 shares, equal to 6.2% of the outstanding common stock as of 10/06/2025.

Who filed the Schedule 13G for PALI?

The filing was made jointly by Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen under a Joint Filing Agreement.

Does the filing indicate Point72 seeks to control Palisade Bio?

No; the certification states the securities were not acquired to change or influence control and the filing is made under Schedule 13G (passive reporting).

What voting and dispositive power did the reporting persons disclose?

Each reporting person disclosed 0 shares of sole voting and dispositive power and 7,585,611 shares of shared voting and shared dispositive power.

Where are the principal offices for the reporting persons located?

The principal business office is listed as 72 Cummings Point Road, Stamford, CT 06902.
Palisade Bio Inc

NASDAQ:PALI

PALI Rankings

PALI Latest News

PALI Latest SEC Filings

PALI Stock Data

235.77M
120.93M
0.24%
5.92%
3.6%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CARLSBAD